QTc prolongation in patients with schizophrenia taking antipsychotics: Prevalence and risk factors

Background: QTc prolongation is one of the possible complications in patients with schizophrenia taking antipsychotics, which leads to malignant cardiac arrhythmia. No meta-analysis has been reported assessing the prevalence and correlated risk factors for QTc prolongation. Methods: This meta-analys...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Psychopharmacology 2023-10, Vol.37 (10), p.2698811231190864-981
Main Authors: Du, Wei, Ge, Meng-Wei, Hu, Fei-Hong, Jia, Yi-Jie, Zhao, Dan-Yan, Cheng, Yu-Jie, Chen, Hong-Lin
Format: Article
Language:English
Subjects:
Antipsychotics
Arrhythmia
Cardiovascular diseases
Comorbidity
EKG
High density lipoprotein
Mental disorders
Meta-analysis
Psychotropic drugs
Risk factors
Schizophrenia
Sensitivity analysis
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: QTc prolongation is one of the possible complications in patients with schizophrenia taking antipsychotics, which leads to malignant cardiac arrhythmia. No meta-analysis has been reported assessing the prevalence and correlated risk factors for QTc prolongation. Methods: This meta-analysis aimed to assess the evidence for the prevalence of QTc prolongation and correlated risk factors in patients with schizophrenia taking antipsychotics. Web of Science and PubMed were searched according to preset strategy. The quality of research was assessed by the Newcastle–Ottawa Scale (NOS). Results: In all, 15 studies covering 15,540 patients with schizophrenia taking antipsychotics were included. Meta-analysis showed that the prevalence of QTc prolongation in patients with schizophrenia taking antipsychotics was about 4.0% (95% confidence interval (CI): 3.0%–5.0%, p 
ISSN:0269-8811
1461-7285
DOI:10.1177/02698811231190864